Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-24-029472
Filing Date
2024-12-16
Accepted
2024-12-16 16:15:16
Documents
2
Period of Report
2024-12-12

Document Format Files

Seq Description Document Type Size
1 form4-12162024_041213.html 4  
1 form4-12162024_041213.xml 4 3941
2 ex24-12162024_041213.htm EX-24 5790
  Complete submission text file 0001415889-24-029472.txt   11172
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38085 | Film No.: 241551978

Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Issuer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)